newsfilter
← Latest News
GlobeNewswire·

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026